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Abstract
Background:  Fermented milk products have been shown to affect serum cholesterol
concentrations in humans. Kefir, a fermented milk product, has been traditionally consumed for its
potential health benefits but has to date not been studied for its hypocholesterolemic properties.
Methods:  Thirteen healthy mildly hypercholesterolemic male subjects consumed a dairy
supplement in randomized crossover trial for 2 periods of 4 wk each. Subjects were blinded to the
dairy supplement consumed. Blood samples were collected at baseline and after 4 wk of
supplementation for measurement of plasma total, low-density lipoprotein, and high-density
lipoprotein cholesterol and triglyceride concentrations, as well as fatty acid profile and cholesterol
synthesis rate. Fecal samples were collected at baseline and after 2 and 4 wk of supplementation
for determination of fecal short chain fatty acid level and bacterial content.
Results: Kefir had no effect on total cholesterol, low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol or triglyceride concentrations nor on cholesterol fractional synthesis rates
after 4 wk of supplementation. No significant change on plasma fatty acid levels was observed with
diet. However, both kefir and milk increased (p < 0.05) fecal isobutyric, isovaleric and propionic
acids as well as the total amount of fecal short chain fatty acids. Kefir supplementation resulted in
increased fecal bacterial content in the majority of the subjects.
Conclusions: Since kefir consumption did not result in lowered plasma lipid concentrations, the
results of this study do not support consumption of kefir as a cholesterol-lowering agent.
Background
Kefir has anecdotally been recommended for consump-
tion by healthy people to lower risk of chronic diseases in
Soviet countries [1]. In these countries, kefir is provided to
patients for clinical treatment of gastrointestinal and met-
abolic diseases, hypertension, ischemic heart disease and
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allergy [1]. However, supporting literature on kefir's effi-
cacy or mechanism of action to alleviate these symptoms
is scarce [2]. Other fermented dairy products such as yo-
gurt and Gaio have been reported to lower serum choles-
terol concentrations in animals [3–7] and humans [8–
13]. Although contradictory results have been obtained
[14–16], the majority of results from these reports indi-
cate that fermented dairy products, possibly including ke-
fir, possess hypocholesterolemic properties.
Consumption of fermented milk has the potential to in-
crease gut bacterial colonization via a protective effect of
milk protein for survival through the gastrointestinal tran-
sit [17]. Yogurt has been reported to have hypocholester-
olemic properties [3–13]. Kefir contains a greater number
of different bacteria than yogurt. Therefore, it is not
known whether consumption of kefir will have a hypoc-
holesterolemic effect in humans. The aim of the present
research was therefore to determine whether kefir supple-
mentation would alter plasma total cholesterol, HDL-
cholesterol, LDL-cholesterol, triglycerides, and fatty acid
levels in mildly hypercholesterolemic men. Furthermore,
analysis of changes in fecal short chain fatty acid (SCFA)
content and cholesterol fractional synthesis rate were also
conducted in order to elucidate a mechanism of action for
any effects of kefir observed.
Methods
Study design and subjects
Non-smoking men were recruited through advertisements
in local newspapers. Subjects were included in the study if
their total serum cholesterol levels were between 6 and 10
mmol/L. Subjects were excluded if they had a history of
cardiovascular disease, previously diagnosed diabetes, hy-
pertension or hypothyroidism, or were treated with cho-
lesterol-lowering agents. Other exclusion factors included
reported lactose intolerance, alcohol intake of more than
10 drinks/wk and use of antioxidant supplements within
the previous two months. Thirteen men met these criteria,
ages 27 to 61 yr (47 ± 9, x ± SD y). Eleven subjects were
initially recruited and 2 more were added to the group 2
weeks later. Subjects' body mass indices ranged from 26 to
38 kg/m2 (30.2 ± 4.4 kg/m2). Mean serum cholesterol lev-
els at screening were 6.54 ± 0.78 mmol/L. The experimen-
tal procedures and protocol were approved by the Ethical
Committee on Human Research of McGill University. In-
formed consent form was signed by all subjects before the
start of the study.
The diet
A randomized, crossover placebo-controlled design was
used where research subjects consuming self-selected diets
supplemented their intake with 500 mL/d of either kefir
(Liberty Co, Candiac, Quebec) or milk, each over a 4 wk
period. Seven subjects received the kefir supplement in
the first period while 6 subjects received milk first. During
the second supplementation period, subjects consumed
the alternate supplement. Supplementation periods were
separated by a 4 wk washout period. Both products were
flavored with 60 g/serving of either peach or strawberry
puree. The milk supplement was prepared daily by adding
90 mL of skim milk powder to 380 mL of 2% milk and
100 mL of water to produce a volume equal to that of ke-
fir. Both products were thus designed to contain the same
fat and cholesterol content as well as energy value (Table
1). Subjects consumed dairy supplements under supervi-
sion during weekdays and at home over the weekend. Ha-
bitual breakfast foods of each subject were available to
consume with the dairy product. Throughout the trial,
subjects were asked to maintain their habitual diet and ex-
ercise at a level consistent with that before study onset.
Food frequency questionnaires were administered after
the washout period and after period 2 of the trial to assess
changes in consumption of dairy products.
Biological sample collection
Fasting blood samples (20 mL) were taken on days 1, 8,
15, 22, 28 and 29. All blood samples were centrifuged at
1500 rpm for 15 min at 4°C. Plasma and red blood cells
were immediately separated and stored at -80°C for later
analysis. A deuterium (D2O) dose of 0.7 g/kg estimated
body water was given on day 28 of each period for analy-
sis of FSR of cholesterol. Body water was assumed to be
60% of total body weight. Subjects were supplied with
deuterium-labeled drinking water (0.93 g D2O/L of wa-
ter) over the 24 h period following the initial deuterium
dosing to maintain body water enrichment at plateau. A
final fasting blood sample was taken exactly 24 h after the
pre-dose sample. Samples of fecal material were collected
by each subject on day before the onset of each period
(day 0) and at the end (day 28) of each supplementation
period.
Table 1: Comparison of the nutritive value of kefir and milk
Kefir Milk
Unit/500 mL
Energy, kJ (kcals) 1200 (287) 1200 (287)
Fat, g 7.6 7.6
Protein, g 23.6 23.6
Carbohydrates, g 31.2 31.2
Cholesterol, mg 311 35
1 Extrapolated from originating milk.BMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/1
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Cholesterol analyses
Total cholesterol, HDL-cholesterol, and triglyceride con-
centrations in plasma at each time point were analyzed in
quadruplicate using a VP Auto-analyzer (Abbott Instru-
ments, Montréal, Québec). The instrument was calibrated
using reagents and known standard concentrations of to-
tal cholesterol, HDL-cholesterol, and triglycerides (Sigma
Laboratories, Oakville, Ontario). Low-density lipoprotein
cholesterol levels were calculated using the Friedewald
formula [18].
Cholesterol synthesis measurement
For measurement of daily rate of cholesterol synthesis, li-
pids were extracted from approximately 2 g of red blood
cells [19]. Extracted lipids were spotted on thin-layer silica
gel plates (20 cm ×  20 cm, 250 mm). Unesterified choles-
terol bands were recovered and combusted to obtain the
resulting combustion water. Plasma water deuterium en-
riched samples were diluted 6 times to reduce the level of
enrichment to working levels. Analysis of product hydro-
gen gas deuterium enrichment was achieved using a dual
inlet ratio mass spectrometer (VG Isogas 903D, Cheshire).
The mass spectrometer was calibrated daily using SMOW
and GISP standards.
Cholesterol FSR was defined as the daily fraction of free
exchangeable cholesterol that is newly synthesized. FSR
was calculated from the measured change in product deu-
terium enrichment in 24 h relative to the maximum pre-
cursor deuterium enrichment determined from the body
water pool [20].
Fecal pH, SCFA and bacterial contents
Fecal samples were collected from 11 subjects since 2 sub-
jects were recruited into the trial after the samples from
the first subjects were collected. Samples were collected in
clean plastic containers, refrigerated overnight and then
aliquoted. Fecal material (2 g) was added to a glass vial
containing 8 mL of distilled water, the contents mixed and
then frozen until pH measurements were taken. Fecal ma-
terial (2 g) was added to a glass vial containing 8 mL of
80% ethanol, the contents mixed and then stored at -4°C
until extracted for SCFA analyses. Samples were extracted
using the method of Erfle et al [21], using isocaproic acid
as an internal standard. A Perkin Elmer Autosystem gas
chromatograph fitted with a 30 m DB-FFAP capillary col-
umn (0.25 mm ID, 0.25 µm) (J&W Scientific, Brockville,
Ontario) was used to quantify acetic, propionic, isobutyr-
ic, butyric, isovaleric, and valeric acid by comparing peak
areas to those of pure standards of known concentration.
Fecal dry matter was determined by weighing triplicate fe-
cal samples before and after heating at 90°C for 24 h. Data
were expressed on a per g dry matter basis.
Statistical analyses
Endpoints (average of days 28 and 29) and changes from
baseline for plasma TC, LDL-cholesterol, HDL-cholester-
ol, and TG concentrations for each period were compared
for treatment differences using paired Student's t-test
(SAS/STAT version 6.12, SAS Institute, Cary, NC). Differ-
ences between cholesterol FSR after kefir and milk supple-
mentation were also compared using Student's paired t-
test. Plasma fatty acid proportions on day 28 of each
phase were compared using Student's t-test. Repeated
measures analysis of variance of results was carried out us-
ing the General Linear Model Procedure (SAS/STAT ver-
sion 6.12, SAS Institute, Cary, NC) to analyse differences
in fecal SCFA with diet and time as variables in the model.
Data for pH were transformed to their anti-logarithm be-
fore statistical analyses, as suggested by Carman et al [22].
Data are reported as mean ± SD.
Results
According to our observations, subjects complied with the
protocol, with one exception where a subject did not con-
sume the placebo product. Gastrointestinal disturbances
were reported during both supplementation periods. Two
subjects reported cramping and constipation at the onset
of kefir supplementation. With milk consumption, one
subject complained of feelings of bloating and having
loose stools, while two subjects reported increased stool
frequency or cramps. All complaints occurred during the
first week of supplementation with kefir or milk. After the
initial week, both products were well tolerated. Subjects
consumed the same breakfast foods in both supplementa-
tion periods.
Initial mean body weight of subjects prior to kefir and
milk supplementation was 90.2 ± 4.0 kg and 90.3 ± 4.1 kg,
respectively. Individual body weights varied by -0.9 to 2.7
kg and -3.2 to 1.4 kg during kefir and milk supplementa-
tion, respectively (not significant).
Percent changes in total plasma cholesterol and HDL-cho-
lesterol concentrations of subjects after kefir and milk
supplementation periods are shown in Figure 1. There was
no effect of diet or time on total, HDL- and LDL-cholester-
ol concentrations. Data at baseline, endpoint and change
during each supplementation period are shown in Table
2. The endpoint plasma total cholesterol levels after kefir
supplementation (6.51 ± 1.05 mmol/L) was not different
from that after milk supplementation (6.00 ± 1.25 mmol/
L). Changes in TC concentrations from baseline were not
different between kefir and milk supplementation. For
HDL-cholesterol concentrations, the endpoint values
were 1.05 ± 0.22 mmol/L after kefir supplementation and
1.02 ± 0.22 mmol/L after milk supplementation. There
was no difference between kefir and milk in the change in
HDL-cholesterol concentrations from baseline. Similarly,BMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/1
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the endpoint LDL-cholesterol concentration after kefir
supplementation (5.43 ± 1.17 mmol/L) and change in
LDL-cholesterol from baseline (0.01 ± 0.68 mmol/L) were
not different from milk supplementation (4.93 ± 1.22
mmol/L and -0.13 ± 0.97 mmol/L, respectively). There
was no effect of kefir or milk consumption on total cho-
lesterol: HDL-cholesterol or LDL: HDL-cholesterol ratios.
Endpoint triglyceride concentrations were also not affect-
ed by kefir or milk supplementation (3.12 ± 1.51 vs 3.21
± 1.58 mmol/L, respectively, Figure 1). Triglyceride con-
centrations at baseline, endpoint and change during each
supplementation period were not significantly different
between kefir and milk consumption and are shown in ta-
ble 2.
Fractional synthesis rates for red cell free cholesterol were
not different after kefir supplementation relative to milk
supplementation (Figure 2). The mean group FSR were
0.057 ± 0.043 and 0.043 ± 0.033 pools/d for kefir and
milk supplementation, respectively.
Of the 11 subjects from whom fecal samples were collect-
ed, 8 (73%) were found to have increased bacterial con-
centration with kefir supplementation. Only 3 (27%) of
the subjects had greater fecal bacterial counts after milk
supplementation. There was no correlation between fecal
bacterial content and any of the blood lipid parameters
analyzed.
Acetic acid was the fecal SCFA found in highest concentra-
tions followed by propionic acid and then butyric acid
both at baseline and 28 d (Table 3). The ratio of acetic/
propionic/butyric was approximately 45/17/15 at 0 d for
both groups. Significant (p < 0.05) time effects were
found for isobutyric, isovaleric, propionic and the total
amount of SCFA. For all four acids, day 28 values were
greater than day 0 values for both the kefir and the milk
treatments. There was no treatment effect on fecal SCFA
levels. Fecal pH measurements were not affected by treat-
ment.
Discussion
Results of this study do not support the use of kefir in the
management of hyperlipidemia. Neither kefir nor milk
supplementation decreased total cholesterol, HDL-cho-
lesterol, LDL-cholesterol, or triglyceride concentrations.
Similarly, there was no difference in cholesterol FSR be-
tween supplementation periods. In addition, plasma fatty
acids levels remained constant throughout both supple-
mentation phases. Both kefir and milk supplementation
resulted in increased SCFA recovery in fecal material over
time but these changes in SCFA were not significantly dif-
ferent between treatments.
Kefir is an ancient fermented milk product that originates
in the Caucasian mountains of Asia. It has been widely
recommended in Soviet countries for consumption by
healthy individuals as well as by patients with gastrointes-
tinal and metabolic disease, hypertension, ischemic heart
disease and allergy [1]. However, literature supporting ke-
fir's proposed health benefits is scarce [2]; we must thus
rely on studies conducted on yogurts and other fermented
dairy products regarding its efficacy.
Figure 1
Change in plasma total cholesterol, HDL-cholesterol and
triglyceride levels in male subjects after kefir and milk supple-
mentation.  = kefir supplementation; ▪ = milk supplementa-
tion. Values are means ± SD, n = 13.
Figure 2
Comparison of fractional synthetic rates of cholesterol after
kefir and milk supplementation.  = kefir supplementation; ▪
= milk supplementation. Values are means ± SD, n = 13.BMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/1
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This study is the first conducted to establish whether kefir
has probiotic activity on plasma cholesterol concentra-
tions and its synthesis. Our hypothesis was that fermented
milk products could reduce circulating cholesterol levels.
Other fermented milk products had previously been
shown to have hypocholesterolemic properties in hu-
mans [8–13]. Several strains of bacteria, such has Lactoba-
cilli and Streptococci, have been shown to reduce serum
cholesterol levels in men [8,13]. These bacteria are nor-
mally transient microorganisms in the gastrointestinal
tract (GIT), entering with food or saliva. Chronic inges-
tion of fermented dairy products, which contain milk pro-
teins that are protective for bacterial survival throughout
the GIT [17], can lead to modifications of the colonic flora
[23]. In the GIT, bacteria can produce several effects that
can result in lower plasma cholesterol levels.
One mechanism by which colonic bacteria can alter cho-
lesterol concentrations in plasma is via bile acid deconju-
gation. Deconjugated bile acids are excreted in the feces
[5], whereas non-conjugated bile acids are recycled to the
liver via the enterohepatic circulation. Their excretion in
fecal material results in increased cholesterol use for de
novo bile acid synthesis. Decreased cholesterol synthesis
would result in decreased body cholesterol pools. This
would in turn lead to lower total to LDL-cholesterol pools
and diminish cardiovascular risk. Data to support this
mechanism were not obtained in the present study. Al-
though this mechanism was not explored in the present
study, data suggest that bile acid deconjugation is a plau-
sible means by which bacteria can modulate plasma cho-
lesterol concentrations.
Colonic bacteria could also exert a hypocholesterolemic
effect via their production of SCFA. Wolever et al [24]
showed that colonic propionate inhibits acetate's choles-
terol-generating effects. Therefore, for gut bacterial fer-
mentation to be hypocholesterolemic, sufficient
propionate must be produced to offset the effects of ace-
tate, which is a precursor for cholesterol synthesis. In-
Table 2: Plasma lipid concentrations (mmol/L) with consumption of a kefir or milk supplement for 28 d.
Supplement TC HDL-C LDL-C TG
Kefir Baseline 6.46 ± 1.43 1.04 ± 0.29 5.41 ± 1.45 3.03 ± 1.87
Endpoint 6.51 ± 1.13 1.05 ± 0.22 5.43 ± 1.17 3.03 ± 1.52
Change 0.05 ± 0.74 0.01 ± 0.19 0.01 ± 0.68 0.00 ± 1.16
Milk Baseline 6.08 ± 1.04 1.01 ± 0.25 5.06 ± 1.04 2.87 ± 1.60
Endpoint 6.00 ± 1.25 1.02 ± 0.22 4.93 ± 1.22 3.01 ± 1.30
Change -0.08 ± 0.89 0.00 ± 0.27 -0.13 ± 0.97 0.14 ± 0.87
Values are means ± SD, n = 13. Endpoints and change from baseline were tested for differences between diets with paired Student's t-tests.
Table 3: Fecal short chain fatty acid (µmol/L per g dry matter) and pH after kefir or milk consumption
KEFIR MILK
SCFA Day 0 Day 28 Day 0 Day 28
Acetic 247 ± 110 278 ± 129 228 ± 77 269 ± 104
Butyric 80 ± 53 99 ± 61 77 ± 38 75 ± 36
Isobutyric1 8.6 ± 4.1 10 ± 6.9 7.8 ± 2.5 11 ± 3.9
Valeric 13 ± 6 13 ± 6 13 ± 7 14 ± 7
Isovaleric1 14 ± 5 16 ± 8 12 ± 4 17 ± 6
Propionic1 95 ± 52 117 ± 66 85 ± 42 105 ± 61
Total SCFA1 458 ± 192 535 ± 239 423 ± 149 492 ± 196
Fecal (pH) 6.5 ± 0.5 6.8 ± 0.6 6.5 ± 0.5 6.7 ± 0.4
Values are means ± SD, n = 12. 1significant effect of time during both kefir and milk supplementation, p < 0.05.BMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/1
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creasing gut bacterial content and composition may result
in altered patterns of SCFA production in the colon that
could result in beneficial effects on plasma cholesterol lev-
els. Our data would indicate that the bacteria in kefir may
not produce sufficient propionate to be effective in im-
pacting on cholesterol synthesis.
In the present study, no effect of kefir or milk was ob-
served on lipid levels. The lack of significant effect of kefir
on total cholesterol concentration is similar to studies us-
ing milk inoculated with bacteria reported by Thompson
et al [15] and De Roos et al [16] as well as animal studies
using fermented milk as observed Rao et al [7]. However,
several other studies did show a positive effect of milk
[25,26] and fermented milks [8,10,13]. The presence of
confounders, such as the fat content of the diets [14,15]
and undefined bacterial composition [14] and concentra-
tion [15] account for differences in the results obtained
and make comparisons between studies difficult. Also, the
use of a proper placebo for studies investigating ferment-
ed milks is problematic since milk has been shown to pos-
sess hypocholesterolemic properties [25,26].
Kefir supplementation, but not milk, produced a signifi-
cant increase in fecal propionic acids without an accom-
panying change in fecal acetic acid levels. Therefore,
present data suggest that the rise in propionate was not
sufficient to inhibit acetate's actions as a precursor for
cholesterol synthesis. As our results show, cholesterol syn-
thesis was not altered by kefir consumption, and thus,
plasma cholesterol concentrations were maintained at
baseline levels. Thus, the lack of effect of kefir on plasma
cholesterol concentrations could have been due in part to
a lack of sufficient increase in propionic acid concentra-
tions. Further studies are required to establish the level of
ingested bacteria needed to result in larger increases in
propionic acid production. The level of propionic acid
production necessary to produce a desirable effect on
blood cholesterol profile also remains to be determined.
The lack of effect of kefir on plasma lipid concentrations
in this trial may have several possible explanations. If bile
acid deconjugation by bacteria is the main mode of action
of bacteria on plasma cholesterol levels, then perhaps the
bacterial content of the kefir was not adequate to cause a
sufficient rise in colonic bacterial content. The kefir sup-
plement consumed in this trial contained 109 colony-
forming units (CFU). Saxelin et al [27] found that a bacte-
rial concentration of 1011 was required in order to pro-
duce colonization in all subjects. In this study only 8 out
of 11 subjects analyzed for fecal bacterial content con-
tained the minimum detection level of 103 CFU/g dry
matter. On the other hand, if the increased propionate
level is the major mechanism of action, then perhaps the
type of bacteria present in kefir do not preferentially pro-
duce propionate over acetate and hence, would not inhib-
it cholesterol synthesis and lead to diminished circulating
cholesterol levels.
Conclusions
Although it is not possible from our data to firmly estab-
lish the reasons for the lack of effect of kefir on plasma
cholesterol levels, present results do not support con-
sumption of kefir as a probiotic to lower plasma cholester-
ol levels. The type and concentration of bacteria contained
in kefir may not have been adequate to produce an impact
on cholesterol metabolism. Thus, in the amounts given in
this study, kefir consumption does not affect cholesterol
metabolism and would therefore not be of clinical value
in the management of hypercholesterolemia.
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